|
Case
| HBS Case Collection
|
2010
Merck: Investing in Science-Based Business (Abridged)
by
Ananth Raman and Inga Katharina Maurer
|
Abstract
Ray Gilmartin faces a dilemma. His company's credibility has been damaged by the recent withdrawal of Vioxx, a multi-billion dollar drug. Moreover, the withdrawal of Vioxx would imply that Merck would fail to meet analysts' earnings expectations for 2005 unless Gilmartin cuts the R&D budget. Cutting the budget might hurt morale and productivity in Merck labs.
Keywords: Factories, Labs, and Plants;
Cost Management;
Production;
Research and Development;